Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 10—October 2020
Dispatch

Silent Circulation of Rift Valley Fever in Humans, Botswana, 2013–2014

Claire E. Sanderson, Ferran Jori, Naazneen Moolla, Janusz T. Paweska, Nesredin Oumer, and Kathleen A. AlexanderComments to Author 
Author affiliations: Virginia Tech, Blacksburg, Virginia, USA, and Chobe Research Institute, Center for African Resources:; Communities, Animals, and Land Use, Kasane, Botswana (C.E. Sanderson, K.A. Alexander); Animals, Health, Territories, Risks, Ecosystems Unit, Université de Montpellier, Montpellier, France, and Botswana College of Agriculture, Gaborone, Botswana (F. Jori); National Institute of Communicable Diseases, Sandringham-Johannesburg, South Africa (N. Moolla, J.T. Paweska); University of the Witswatersrand, Johannesburg (J.T. Paweska); Botswana Ministry of Health, Gaborone (N. Oumer).

Cite This Article

Abstract

We evaluated the prevalence of Rift Valley fever virus IgG and IgM in human serum samples (n = 1,276) collected in 2013–2014 in northern Botswana. Our findings provide evidence of active circulation of this virus in humans in the absence of clinical disease in this region.

The World Health Organization considers Rift Valley fever (RVF) a priority disease because of its substantial public health impact and the lack of available interventions to prevent and halt epidemics (1). RVF virus (RVFV) is primarily transmitted to animals through infected Aedes and Culex mosquitoes, while human transmission has been attributed to direct contact with the blood and tissues of RVFV-infected livestock. RVF outbreaks have been challenging to forecast because quiescent interepidemic or interepizootic years are irregularly interspersed with epizootic years. Both RVFV-infected mosquitoes and terrestrial mammals are postulated to play a role in virus maintenance during interepizootic years (2).

In Botswana, RVFV exposure and infection dynamics are incompletely understood. Despite numerous large-scale RVF outbreaks across southern Africa being reported to the World Animal Health Information Database (https://www.oie.int/wahis_2/public/wahid.php/Wahidhome/Home), no outbreaks in people have been detected in Botswana, even though previous surveys have found serologic evidence of virus exposure in humans (1959, 1984–1986), African buffalo (Syncerus caffer), and domestic cattle (35). Thus far, according to the World Animal Health Information Database, RFV disease outbreaks in Botswana have only been reported in livestock (n = 4 outbreaks). It is presently unclear why low-level virus circulation has not been associated with detectable outbreaks in humans or how the virus is maintained during interepizootic years. Here, we evaluate archived human serum samples for evidence of RVFV-specific IgG and IgM and discuss the implications for public health in this region.

The Study

Figure

Thumbnail of Number of Rift Valley fever virus IgG-positive IgG-negative human serum samples by age at time of testing, Botswana. The overlaid red lines represent ages of patients who also tested positive for Rift Valley fever virus IgM. No patients <17 years of age tested IgG positive for Rift Valley fever virus (black outline).

Figure. Number of Rift Valley fever virus IgG-positive IgG-negative human serum samples by age at time of testing, Botswana. The overlaid red lines represent ages of patients who also tested positive for...

We determined the historical occurrence of suspected and documented cases of RVF in the human population in Botswana by evaluating inpatient records from Kasane Primary Hospital (Chobe District, 1962–2019) and nationwide monthly outpatient data from all 17 districts (1985–2019). Human serum samples (n = 1,276; mean age 32 [SD +12], range 1–91; 2013–2014) were collected from government health facilities within the Chobe District and screened using a recombinant nucleocapsid IgG indirect ELISA (6), with positive samples confirmed by inhibition ELISA (7). We screened IgG-positive samples for IgM using IgM-capture ELISA (8). This research was conducted with permission from the Botswana Ministry of Health and the Virginia Tech Institutional Review Board (Permit #11–573). Figure was created in the open source statistical program R version 3.6.1 (https://www.r-project.org) using ggplot2 (https://ggplot2.tidyverse.org).

We found no reports of RVFV infections, confirmed or suspected, from Botswana’s passive health surveillance systems. Despite this, 5% (95% CI 4%–6%) of serum samples tested positive for IgG (mean age 46 [SD +17], range 17–91; Table 1); of these, 11% (95% CI 5%–21%) were positive for IgM (mean age 32 years [SD +8] range 24–47). Both IgG- and IgM-seropositive samples were found across sampled years, but no significant differences could be detected by year of testing (IgG and IgM χ2 = 0.27; p = 0.60) or season (seasonal data for IgG only available for 2013; χ2 = 0.98; p = 0.32). All IgM-positive samples (n = 7), however, were obtained during the wet season (November 2013–February 2014). During the ensuing dry season, a RVF outbreak in livestock (n = 2 cows) in the Chobe enclave in July 2014 was reported to the World Animal Health Information Database. In northern Botswana, rainfall and flood height affect mosquito dynamics, with models showing Culex pipiens mosquitoes to be most abundant in December (9), corresponding to human RVFV serological data previously collected in the region (5). The presence of IgM-positive patients confirms that RVFV was actively circulating in humans in the Chobe District in 2013 and 2014, causing a single outbreak potentially associated with RVFV infection in both humans and livestock.

In South Africa, large RVFV outbreaks have occurred every 20–30 years, and domestic livestock has been implicated in human transmission (10). In Botswana, no human infections have been recorded, nor have explosive outbreaks occurred, suggesting that the dynamics of RVFV transmission and persistence differ between these countries. This difference may be because of differing agricultural production intensities and livestock composition; the Chobe District solely supports subsistence farming and has fewer small domestic ruminants.

Overall, findings significantly differed by sex; men (n = 266, 9%, 95% CI 6%–13%) had higher IgG seroprevalence than women (n = 861, 4%, 95% CI 3%–6%) (χ2 = 4.96, p = 0.03; sex unknown, n = 149; Table 1). In contrast, all IgM-positive patients were female, except for 1, for whom sex was unknown. Sex-specific roles in animal care and food preparation might influence RVFV exposure patterns. In the Chobe District, 54% (95% CI 46%–61%) of interviewed households owned livestock (11), and men predominately cared for (97%, 95% CI 91%–99%; K.A. Alexander et al., unpub. data) and slaughtered large livestock (12). It is unknown why only women were IgM positive; however, women are involved in handling butchered meat in food preparation (13), so differences in exposure times to potentially infected animal tissues and fluids likely influenced RVFV exposure and transmission risk. Women (46%, 95% CI 32%–61%) and men (54%, 95% CI 39%–68%) both care for small livestock (K.A. Alexander et al., unpub. data).

When we sorted patients into 7 age groups, elderly (>80 years old) and aged (65–79 years old) patients had significantly higher seroprevalence levels than other age groups (Table 2). A significant difference was also detected between middle-aged (45–64 years old) patients and young adults (20–24 years old) (Table 2), possibly because older patients have been exposed more often to RVF outbreaks as a function of time. However, low sample sizes in the aged and elderly groups may have skewed our results. All IgM-positive patients were 24–47 years of age. We found no evidence of RVFV in patients <17 years old, likely because of a lack of exposure to diseased animals (Figure).

Patient visits were primarily for routine health checks or noninfectious disease treatment, suggesting that RVF can occur with only mild or subclinical manifestations in affected people, which concurs with reports from other RVF-endemic regions (13). However, some IgG-positive patients in our study did have symptoms possibly attributable to RVF infection, including leg paralysis, swollen legs, and arthritis. Pregnancy was reported in 3 IgM-positive patients (43%, 95% CI 16%–75%); the outcomes of these pregnancies are unknown, but previous studies indicate that women infected with RVFV are 7 times more likely to miscarry than uninfected women (14).

Where data were collected, we found a significant association between IgG seroprevalence and HIV status (χ2 = 6.4; p = 0.01); 48% (95% CI 36%–61%) of IgG-positive patients were also HIV positive. It is unknown when these patients became infected with RVFV or HIV, but concurrent infection can increase the development of RVF symptoms involving the central nervous system, as well as fatality rates (15). Although nearly one third of IgM-positive patients were infected with HIV (29%, 95% CI 8%–64%), we could not detect a significant association with HIV status (χ2 = 0.67; p = 0.4), likely because of the small sample size.

Conclusions

RVFV appears to be endemically circulating in northern Botswana, with people likely exposed to the virus regularly over time. Whereas viral reservoirs are uncertain, both livestock and wildlife present potential opportunities for human exposure to RVFV. In Botswana, government hospitals use syndromic diagnoses to treat patients; however, because no human cases have been reported and the disease can be asymptomatic, many RVF cases are likely misdiagnosed or undiagnosed. Increased diagnostic capacity and public health awareness of RVFV in Botswana is required to further elucidate risk factors associated with human infection, especially in high-risk populations. These findings underscore the urgent need for more intensive investigations into RVFV transmission and persistence at the human-animal vector interface.

Claire E. Sanderson is a research associate in the Fish and Wildlife Conservation Department at Virginia Tech and the Research Coordinator at the Center for African Resources: Communities, Animals, and Land Use (CARACAL). Her research interests broadly encompass disease ecology, behavioral ecology, conservation biology, and population genetics.

Top

Acknowledgments

We thank the Botswana Ministry of Health and the Chobe District Health Team for their support on this project.

This project was funded by the National Science Foundation Dynamics of Coupled Natural and Human Systems (#1518486) and Ecology and Evolution of Infectious Diseases (#1518663).

Top

References

  1. Mehand  MS, Al-Shorbaji  F, Millett  P, Murgue  B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Res. 2018;159:63–7.
  2. Olive  M-M, Goodman  SM, Reynes  J-M. The role of wild mammals in the maintenance of Rift Valley fever virus. J Wildl Dis. 2012;48:24166. DOIPubMed
  3. Jori  F, Alexander  KA, Mokopasetso  M, Munstermann  S, Moagabo  K, Paweska  JT. Serological evidence of Rift Valley fever virus circulation in domestic cattle and African buffalo in northern Botswana (2010–2011). Front Vet Sci. 2015;2:63. DOIPubMed
  4. Kokernot  RH, Szlamp  EL, Levitt  J, McIntosh  BM. Survey for antibodies against arthropod-borne viruses in the sera of indigenous residents of the Caprivi Strip and Bechuanaland Protectorate. Trans R Soc Trop Med Hyg. 1965;59:55362. DOIPubMed
  5. Tessier  SF, Rollin  PE, Sureau  P. Viral haemorrhagic fever survey in Chobe (Botswana). Trans R Soc Trop Med Hyg. 1987;81:699700. DOIPubMed
  6. Jansen van Vuren  P, Potgieter  AC, Paweska  JT, van Dijk  AA. Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA. J Virol Methods. 2007;140:10614. DOIPubMed
  7. Paweska  JT, Mortimer  E, Leman  PA, Swanepoel  R. An inhibition enzyme-linked immunosorbent assay for the detection of antibody to Rift Valley fever virus in humans, domestic and wild ruminants. J Virol Methods. 2005;127:108. DOIPubMed
  8. Paweska  JT, Burt  FJ, Swanepoel  R. Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J Virol Methods. 2005;124:17381. DOIPubMed
  9. Pachka  H, Annelise  T, Alan  K, Power  T, Patrick  K, Véronique  C, et al. Rift Valley fever vector diversity and impact of meteorological and environmental factors on Culex pipiens dynamics in the Okavango Delta, Botswana. Parasit Vectors. 2016;9:434. DOIPubMed
  10. Ngoshe  YB, Avenant  A, Rostal  MK, Karesh  WB, Paweska  JT, Bagge  W, et al. Patterns of Rift Valley fever virus seropositivity in domestic ruminants in central South Africa four years after a large outbreak. Sci Rep. 2020;10:5489. DOIPubMed
  11. Alexander  K, Ramotadima  M, Sanderson  CE. The power of consensus: developing a community voice in land use planning and tourism development in biodiversity hotspots. Ecosyst Serv. 2018;30:35061. DOI
  12. Fafetine  J, Neves  L, Thompson  PN, Paweska  JT, Rutten  VP, Coetzer  JA. Serological evidence of Rift Valley fever virus circulation in sheep and goats in Zambézia Province, Mozambique. PLoS Negl Trop Dis. 2013;7:e2065. DOIPubMed
  13. Mooketsi  C. Butchery styles and the processing of cattle carcasses in Botswana. PULA: Botswana Journal of African Studies. 2001;15:10824.
  14. Baudin  M, Jumaa  AM, Jomma  HJE, Karsany  MS, Bucht  G, Näslund  J, et al. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob Health. 2016;4:e86471. DOIPubMed
  15. Mohamed  M, Mosha  F, Mghamba  J, Zaki  SR, Shieh  W-J, Paweska  J, et al. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am J Trop Med Hyg. 2010;83(2_Suppl):22–7.

Top

Figure
Tables

Top

Cite This Article

DOI: 10.3201/eid2610.191837

Original Publication Date: September 07, 2020

Table of Contents – Volume 26, Number 10—October 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Kathleen Alexander, Virginia Tech, Integrated Life Sciences Building, 1981 Kraft Dr, Blacksburg, VA 24060, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: June 30, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external